MB49
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
MB49 is a urothelial carcinoma cell line derived from a male C57BL/6 mouse by exposing primary bladder cells to DMBA (7,12-dimethylbenz[a]anthracene) for 24 hours and subsequent culturing. The cell line, despite its male origin, lacks the Y-chromosome and male-specific antigen expression. Transplanted MB49 cells in syngeneic mice have been shown to generate carcinomas. Recent research has indicated its sensitivity to testosterone and human chorionic gonadotropin (hCG). MB49 is categorized as a cold tumor phenotype due to its minimal infiltration of CD8+ and CD4+ T cells and the significant presence of immunosuppressive myeloid populations.
Why choose MB49 from AcceGen?
Choosing MB49 from AcceGen ensures reliable and contaminant-free research as each vial contains ≥ 1×106 viable cells. The cells undergo thorough testing to verify 
their negative status for infectious diseases. Additionally, they are confirmed to be of pure mouse origin and free from contamination by rat, Chinese hamster, Golden Syrian hamster, human, and non-human primate species. Moreover, the cells are mycoplasma-free, ensuring the validity of experimental results and data integrity.
| Product Code | MB-49 |
| Species | Mouse |
| Cat.No | ABC-TC223S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bladder |
| Disease | Urothelial Cancer |
| Storage | Liquid Nitrogen |
| Product Type | Mouse Bladder Cancer Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
The MB49 mouse urothelial carcinoma cell line serves as a valuable tool for studying bladder cancer both in vitro and in vivo. With its potential as an immuno-oncology model, MB49 holds substantial promise in drug development research. Its responsiveness to checkpoint inhibitor therapy and costimulatory antibody therapy makes it particularly suitable for investigating novel treatment combinations involving checkpoint inhibitors or costimulatory molecules. Therefore, MB49 offers a versatile platform for studying the efficacy and mechanisms of immunotherapies, contributing to advancements in cancer treatment strategies.
